Work

Apparent treatment-resistant hypertension and cardiorenal outcomes

Year: 2026
Type: article
Study design: Observational Study
Abstract: Apparent treatment-resistant hypertension (aTRH) is associated with adverse cardiovascular and kidney outcomes, but contemporary real-world estimates that account for time at risk and distinguish incident from pre-existing disease remain limited. We performed a retrospective cohort study of 83,156 adults receiving outpatient care at Naples Comprehensive Health between April 2022 and April 2024. Baseline blood pressure (BP) phenotype was determined from the first recorded office BP and the antihypertensive medication list, with goals individualised by cardiovascular disease (CVD) history (< 130/80 mm Hg with CVD; <140/90 mm Hg without CVD). Patients were classified as having normal BP, controlled BP on therapy, uncontrolled hypertension not meeting resistance criteria (non-TRH), or aTRH. The primary outcome was a composite of incident myocardial infarction, stroke, or heart failure. For every outcome, patients with that condition recorded at baseline were excluded from the denominator. Associations were estimated with multivariable Poisson models incorporating a person-time offset, yielding incidence rate ratios (IRRs); all-cause mortality was analysed with Cox proportional hazards regression. Among 83,156 adults, 7,299 (8.8%) met criteria for aTRH, of whom 5,362 (73.5%) were above goal on three or more agents and 1,937 (26.5%) were at goal on four or more. Over 130,618 person-years (mean follow-up 18.8 months), the incidence of the primary composite outcome rose stepwise across phenotypes, from 25.6 per 1,000 person-years with normal BP to 132.7 with aTRH. After adjustment for age, sex, race, diabetes, prior CVD, smoking, obesity, chronic kidney disease, dyslipidaemia and malignancy, aTRH was associated with the primary composite outcome (IRR 2.46; 95% CI, 2.26–2.68), heart failure (3.31; 2.96–3.69), acute kidney injury (2.86; 2.53–3.24), chronic kidney disease (2.45; 2.23–2.69), end-stage kidney disease (4.46; 2.50–7.96) and all-cause mortality (hazard ratio 1.78; 1.41–2.26). aTRH was persistent: 68.4% remained in the aTRH category at follow-up, whereas 22.7% transitioned to controlled BP. Findings were unchanged across four alternative phenotype definitions. In routine outpatient care, aTRH affected approximately one in eleven adults, was largely persistent over a mean of 18.8 months, and was independently associated with incident cardiovascular and kidney disease and with death. The gradient was steepest for heart failure and kidney outcomes, supporting earlier recognition and systematic treatment optimisation.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7236078676
FWCI:
Cites:
Cited by:
Related to: 10